The more you understand about primary immunodeficiency (PI), the better you can live with the disease or support others in your life with PI. Learn more about PI, including the various diagnoses and treatment options.
Living with primary immunodeficiency (PI) can be challenging, but you’re not alone—many people with PI lead full and active lives. With the right support and resources, you can, too.
Be a hero for those with PI. Change lives by promoting primary immunodeficiency (PI) awareness and taking action in your community through advocacy, donating, volunteering, or fundraising.
Whether you’re a clinician, researcher, or an individual with primary immunodeficiency (PI), IDF has resources to help you advance the field. Get details on surveys, grants, and clinical trials.
The U.S. Food and Drug Administration (FDA) has amended the emergency use authorizations (EUAs) for an additional COVID-19 mRNA vaccine dose (Pfizer and Moderna) for certain immunocompromised individuals. Those with primary immunodeficiencies are not specifically listed in the FDA announcement but may be covered as individuals diagnosed with conditions that are considered to have an equivalent level of immunocompromise to those with solid organ transplant recipients.
In addition, the Centers for Disease Control (CDC) Advisory Committee on Immunization Practices (ACIP) met earlier today and recommended a third COVID-19 dose for those who are moderate to severely immunocompromised. Their recommendation included those with moderate and severe primary immunodeficiency.
According to the CDC ACIP:
attempts should be made to match the additional dose type to the one used in the original set of shots someone receives. But if that is not feasible, the committee said an additional dose with the other vaccine is permitted. According to the recommendations, the additional dose should be administered at least 28 days after completion of the primary vaccine series.
Please note:
Our recommendation is to consult with your physician for guidance regarding your need for an additional dose and, if needed, the best way to access a third shot. For additional treatment questions, please see IDF’s statement on August 6 that addresses treatments and protections to COVID-19.
Receive news and helpful resources to your cell phone or inbox. You can change or cancel your subscription at any time.
The Immune Deficiency Foundation improves the diagnosis, treatment, and quality of life for every person affected by primary immunodeficiency.
We foster a community that is connected, engaged, and empowered through advocacy, education, and research.
Combined Charity Campaign | CFC# 66309